- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04572243
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)
January 18, 2024 updated by: Eisai Inc.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
58
Phase
- Phase 3
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Eisai Medical Information
- Phone Number: 1-888-274-2378
- Email: esi_medinfo@eisai.com
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, AB T3B 6A8
- Terminated
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada, T6G 1C9
- Recruiting
- Stollery Children's Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3N1
- Not yet recruiting
- BC Children's Hospital
-
-
Ontario
-
London, Ontario, Canada, N6A 4G5
- Recruiting
- Children's Hospital - VH, London Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 1X8
- Terminated
- University of Toronto Division of Hematology Oncology/The Hospital for Sick Children
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35226
- Recruiting
- Children's of Alabama / University of Alabama at Birmingham
-
-
California
-
Los Angeles, California, United States, 90095
- Terminated
- University of California Los Angeles (UCLA)
-
San Diego, California, United States, 92123
- Not yet recruiting
- UCSD Rady's Children's Hosptial
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
-
Florida
-
Gulf Breeze, Florida, United States, 32561
- Terminated
- Northwest Florida Clinical Research Group
-
Hollywood, Florida, United States, 33021
- Not yet recruiting
- Joe DiMaggio Children's Hospital
-
Miami, Florida, United States, 33155
- Terminated
- Miami Children's Hospital - Nicklaus Children's Hospital
-
Winter Park, Florida, United States, 32789
- Recruiting
- Pediatric Neurology, P.A.
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Terminated
- Rare Disease Research Center Pediatrics, LLC
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Recruiting
- Mid-Atlantic Epilepsy and Sleep Center - Bethesda
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Terminated
- Spectrum Health/ Helen DeVos Children's Hospital
-
-
Missouri
-
Columbia, Missouri, United States, 65201
- Recruiting
- University of Missouri, Department of Child Health, Division of Neurology
-
-
New Jersey
-
Livingston, New Jersey, United States, 07039
- Terminated
- Institute of Neurology and Neurosurgery at Saint Barnabas
-
-
New York
-
New Hyde Park, New York, United States, 10075
- Terminated
- Northwell Health - Neuroscience Institute at Great Neck
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Comprehensive Epilepsy Center
-
New York, New York, United States, 10019-1147
- Recruiting
- New York Medical College
-
New York, New York, United States, 11021
- Terminated
- NorthWell Health - Lennox Hill Hospital
-
Rochester, New York, United States, 14642
- Terminated
- University of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7025
- Terminated
- University of North Carolina
-
Durham, North Carolina, United States, 27710
- Terminated
- Duke University Hospital Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Terminated
- Children's Hospital of Pittsburgh of UPMC
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, United States, 98105
- Terminated
- Seattle Children's Hospital
-
Tacoma, Washington, United States, 98405
- Terminated
- MultiCare Institute for Research & Innovation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 months and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
Participants must meet all of the following criteria to be included in this study:
- Male or female, age 2 years and older at the time of informed consent
- Diagnosis of epilepsy with Dravet syndrome
- Has at least 4 convulsive seizures during the 4 weeks of baseline
- Current treatment with antiepileptic drugs must be stable for at least 4 weeks before screening, and be expected to remain stable throughout the study
Key Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from this study:
- Use of lorcaserin within 4 weeks before screening, or any history of it being discontinued due to lack of efficacy or adverse reactions
- Use of fenfluramine within 2 months before screening, any history of lack of fenfluramine efficacy, or any history of valvulopathy at baseline with history of fenfluramine use
- Recent or concomitant use of serotonergic medications or monoamine oxidase inhibitors
- Presence of progressive central nervous system disease other than Dravet syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lorcaserin (Core Study and Open-label Extension Phase)
Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period.
Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (<) 20, 20 to <40, and greater than or equal to (>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively.
Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively.
Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
|
Lorcaserin oral tablet, administered as oral suspension.
Other Names:
|
Placebo Comparator: Placebo (Core Study) + Lorcaserin (Open-label Extension Phase)
Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period.
Dose will be based on body weight as follows: target dose for participants weighing 10 to <20, 20 to <40, and >=40 kg will be 5, 10, and 20 mg/day respectively.
Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively.
Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
|
Lorcaserin oral tablet, administered as oral suspension.
Other Names:
Placebo matching to lorcaserin oral tablet, administered as oral suspension.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Core Treatment Period (14 Weeks)
Time Frame: Baseline to Week 14
|
Seizure frequency will be based on number of seizures per 28 days, calculated during the baseline period and treatment period as the number of seizures during each respective period divided by the number of non-missing days during each respective period, multiplied by 28.
|
Baseline to Week 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of 50% Responders for Convulsive Seizures in the Core Treatment Period (14 Weeks) Compared to Baseline
Time Frame: Baseline to Week 14
|
A 50 percent (%) responder is defined as a participant with at least 50% reduction in frequency of convulsive seizures per 28 days compared to baseline.
|
Baseline to Week 14
|
Percentage of Participants who are Free From Convulsive Seizures in the Core Treatment Period (14 Weeks)
Time Frame: Up to 14 Weeks
|
Up to 14 Weeks
|
|
Maximum Lorcaserin Plasma Concentration at Steady-state (Cmax,ss) in the Core Treatment Period (14 Weeks)
Time Frame: Up to 14 Weeks
|
Up to 14 Weeks
|
|
Area Under the Plasma Lorcaserin Concentration-time Curve at Steady-state (AUC,ss) in the Core Treatment Period (14 Weeks)
Time Frame: Up to 14 Weeks
|
Up to 14 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 23, 2020
Primary Completion (Estimated)
March 5, 2025
Study Completion (Estimated)
May 28, 2025
Study Registration Dates
First Submitted
September 30, 2020
First Submitted That Met QC Criteria
September 30, 2020
First Posted (Actual)
October 1, 2020
Study Record Updates
Last Update Posted (Estimated)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 18, 2024
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E2023-A001-304
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsies, Myoclonic
-
Autifony Therapeutics LimitedRecruitingMyoclonus Epilepsies, ProgressiveUnited States
-
King's College LondonKing's College Hospital NHS Trust; Charles University, Czech Republic; Hopital... and other collaboratorsRecruitingJuvenile Myoclonic EpilepsyUnited States, Canada, Czechia, Denmark, Estonia, France, Italy, Norway, United Kingdom
-
University of TurkuUnknownUnverricht-Lundborg SyndromeFinland
-
University College, LondonUniversity of North Carolina, Chapel Hill; NYU Grossman School of MedicineRecruitingDentatorubral-Pallidoluysian AtrophyUnited States, United Kingdom
-
Lars Bo AndersenUnknownEpilepsy | Seizure Disorder | Epileptic Seizures | EpilepsiaDenmark
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
National Institute of Neurological Disorders and...Completed
-
Universiteit AntwerpenUniversitaire Ziekenhuizen KU Leuven; KU Leuven; University Hospital, Antwerp; Research...CompletedDravet Syndrome | Severe Myoclonic Epilepsy of InfancyBelgium
-
Eisai LimitedTerminatedEpilepsyAustralia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
Clinical Trials on Lorcaserin
-
Eisai Inc.CompletedObesityUnited States
-
Eisai Inc.CompletedHepatic ImpairmentUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions
-
Eisai Inc.AvailableEpilepsies, Myoclonic | Drug Resistant Epilepsy
-
Eisai Inc.CompletedHealthy | Drug AbuseCanada
-
Johns Hopkins UniversityTerminatedSepsis | Muscle WeaknessUnited States
-
Scripps Whittier Diabetes InstituteEisai Inc.CompletedObesity | Overweight | Weight LossUnited States
-
Eisai Inc.CompletedPharmacokinetics in Obese AdolescentsUnited States
-
Eisai Inc.CompletedRenal ImpairmentUnited States
-
Eisai Inc.Completed